Pierre Kiecolt-Wahl, a dual American/French citizen joined Bryan, Garnier & Co’s European investment banking team as Managing Director, heading up the Equity Capital Markets division in May 2016. Pierre brings over 15 years of international equity capital markets knowledge with organizations such as Bank of America, Lehman Brothers, Jefferies and Citi, based in San Francisco, London and Hong Kong.
Since arriving at Bryan, Garnier & Co, he has led numerous transactions, continuing to strenghthen the firm’s footprint across Europe and the US. Key transactions include: Zealand Pharma Wall-Crossed Follow-On Offering (DKK 143m) | Symetis Euronext IPO & subsequent sale to Boston Scientific ($435m), Celyad Nasdaq & Euronext Publicly Marketed Follow-on Offering (€46m) | Ablynx Nasdaq IPO ($230m) | Medartis Six Swiss IPO (CHF 143m) | Canopy Growth Global Convertible Bond, Toronto Stock Exchange (CAD 600m) and Materialise’s Nasdaq Follow-on Offering ($45m).